Thinking of joining a study?

Register your interest

Become a volunteer?

NCT02610426 | RECRUITING | Breast Carcinoma

Whole Exome Sequencing in Finding Causative Variants in Germline DNA Samples From Patients With Congestive Heart Failure Receiving Therapy for Breast Cancer
Sponsor:

National Cancer Institute (NCI)

Brief Summary:

This research trial studies whole exome sequencing in finding causative variants in germline deoxyribonucleic acid (DNA) samples from patients with congestive heart failure receiving therapy for breast cancer. Studying samples of germline DNA in the laboratory from patients with congestive heart failure receiving therapy for breast cancer may help doctors learn more about changes that occur in DNA and identify biomarkers related to congestive heart failure.

Condition or disease

Breast Carcinoma

Intervention/treatment

Laboratory Biomarker Analysis

Detailed Description:

PRIMARY OBJECTIVES: I. To identify, using next generation sequencing, rare variants of large effect size that impact the risk of congestive heart failure (CHF) in patients from the clinical trial ECOG-5103 (E5103). OUTLINE: Previously collected germline DNA samples are analyzed via whole exome sequencing.

Study Type : OBSERVATIONAL
Estimated Enrollment : 162 participants
Official Title : Exploratory Next Generation Sequencing to Identify Causative Variants for Therapy-Induced Congestive Heart Failure From Breast Cancer Study E5103 Germline DNA Samples
Actual Study Start Date : 2014-03-25
Estimated Primary Completion Date : 2100-01-01
Estimated Study Completion Date : 2100-01-01

Information not available for Arms and Intervention/treatment

Ages Eligible for Study:
Sexes Eligible for Study: ALL
Accepts Healthy Volunteers:
Criteria
Inclusion Criteria
  • * European American patients with DNA available
  • * European American patients who developed CHF and patients who did not develop CHF following a full course of treatment with an anthracycline and bevacizumab
  • * African American cases (based on a drop in left ventricular ejection fraction \[LVEF\] \< 50 or a drop from baseline \> 20 points) and African American controls
Whole Exome Sequencing in Finding Causative Variants in Germline DNA Samples From Patients With Congestive Heart Failure Receiving Therapy for Breast Cancer

Location Details

NCT02610426

Please Choose a site

How to Participate

Want to participate in this study, select a site at your convenience, send yourself email to get contact details and prescreening steps.

Locations

RECRUITING

United States, Massachusetts

Eastern Cooperative Oncology Group

Boston, Massachusetts, United States, 02215